INNOVIVA, INC. Total Assets
INNOVIVA, INC. (INVA) had Total Assets of $1.70 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-05
- 2026-06-30: Assets $1.70B.
- 2026-03-31: Assets $1.84B.
- 2025-12-31: Assets $1.64B.
- 2025-09-30: Assets $1.43B.
| Period end | Assets | Assets as first filed |
|---|---|---|
| 2026-06-30 | $1.70B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.84B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.64B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $1.43B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.33B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $1.25B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $1.30B 10-K · filed 2026-02-25 | |
| 2024-09-30 | $1.23B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $1.22B 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $1.27B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $1.24B 10-K · filed 2025-02-26 | |
| 2023-09-30 | $1.19B 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $1.12B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $1.13B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.23B 10-K/A · filed 2024-03-05 | |
| 2022-09-30 | $1.33B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.14B 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $1.11B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $926.39M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $887.24M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $789.15M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $1.09B 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $999.57M 10-K/A · filed 2022-03-17 | |
| 2020-09-30 | $922.26M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $879.62M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $788.01M 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $724.83M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $675.95M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $642.31M 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $590.11M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $548.19M 10-K · filed 2020-02-19 | |
| 2018-09-30 | $277.69M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $338.69M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $276.75M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $367.34M 10-K · filed 2019-02-19 | |
| 2017-09-30 | $390.97M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $372.02M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $391.87M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $379.00M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $370.54M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $378.11M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $387.83M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $408.93M 10-K · filed 2017-02-28 | $424.07M 10-K · filed 2016-02-24 |
| 2015-09-30 | $437.63M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $462.09M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $488.70M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $521.65M 10-K · filed 2016-02-24 | |
| 2014-09-30 | $553.71M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $605.61M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $605.03M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $681.25M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $666.02M 10-Q · filed 2013-11-01 | |
| 2013-06-30 | $594.70M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $591.52M 10-Q · filed 2013-05-01 | |
| 2012-12-31 | $368.58M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $383.94M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $399.42M 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $217.73M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $258.78M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $283.32M 10-Q · filed 2011-11-02 | |
| 2011-06-30 | $303.12M 10-Q · filed 2011-08-03 | |
| 2010-12-31 | $331.20M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |